One Kendall Square
Building 1400 West, Suite 14303
At AnTolRx, we are approaching the treatment of autoimmune diseases differently–through the development of novel nanoparticle-based therapies to promote antigen-specific immune tolerance. Standard therapies broadly suppress the immune system, inducing side effects that may include life threatening infections and tumors. Thus, there is an unmet clinical need for methods of targeted immune-regulation. Our proprietary drug development approach selectively targets pathogenic immune cells providing a unique tolerogenic signal to induce an anti-inflammatory phenotype and better treat diseases.
Founder and CEO: Mark Carthy
Scientific Founder: Francisco J Quintana, PhD
Member BoD: Satish Jindal, PhD
Scientific Consultant: Vincent Stanton Jr.
Senior Scientist: Jessica Kenison-White
Please click here for AnTolRx's Pipeline.